Dupilumab improves quality of life in atopic dermatitis: Evidence and real-world insights

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intense pruritus, recurrent eczema, and substantial impairment in quality of life (QoL). Affecting up to 20 percent of children and approximately 10 percent of adults in high-income countries, AD places a significant burden on patients and their families, impacting sleep, productivity, and psychosocial well-being. [Br J Dermatol 2021;184:304-309]

Targeted biologic therapies have transformed the management of moderate-to-severe AD. Dupilumab, a fully human monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα), inhibits signalling of IL-4 and IL-13, key cytokines driving type 2 inflammation in AD. By disrupting this pathway, dupilumab addresses core mechanisms underlying skin inflammation, barrier dysfunction, and pruritus. [Allergy 2022;77:3388–3397] Reflecting its central role in type 2 inflammation, dupilumab is indicated in a broad range of conditions, including moderate-to-severe atopic dermatitis (≥6 months), severe type 2 asthma (≥6 years), chronic rhinosinusitis with nasal polyposis, prurigo nodularis, chronic spontaneous urticaria, and eosinophilic COPD. [DUPIXENT (dupilumab) Singapore Prescribing Information. Sanofi; 2025]